<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The risks of <z:mp ids='MP_0000334'>agranulocytosis</z:mp> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in relation to the use of <z:chebi fb="1" ids="35554">cardiovascular drugs</z:chebi> were estimated in a population-based case-control study conducted in Israel and Europe (total population, 23 million) </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="1" ids="35554">Cardiovascular drug</z:chebi> use in the week before <z:hpo ids='HP_0003674'>onset</z:hpo> of illness was compared between 270 patients hospitalized with <z:mp ids='MP_0000334'>agranulocytosis</z:mp> and 1870 hospitalized control subjects </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="2" ids="8499">Propranolol</z:chebi> (relative risk, 2.5), <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> (3.8), digoxin (2.5), and acetyldigoxin (9.9) were significantly associated with <z:mp ids='MP_0000334'>agranulocytosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The excess risks attributable to these drugs ranged from one to three cases per 10 million persons exposed for up to 1 week </plain></SENT>
<SENT sid="4" pm="."><plain>Increased risks were also observed for cinepazide (used by six cases and no control subjects), <z:chebi fb="0" ids="8428">procainamide</z:chebi> (7, 1), and aprindine (5, 1); based on crude relative risk estimates, the excess risks for the latter two drugs were approximately three per million persons exposed for up to 1 week </plain></SENT>
<SENT sid="5" pm="."><plain>The use of <z:chebi fb="1" ids="35554">cardiovascular drugs</z:chebi> in a 5-month period ending 1 month before hospital admission was compared between 152 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and 2180 control subjects </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="47426">Furosemide</z:chebi> was the only significantly associated drug (relative risk, 3.1); the excess risk attributable to any exposure in a 5-month interval was 1.7 per million </plain></SENT>
</text></document>